Tarsus Pharmaceuticals, Inc. TARS Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s accounts payable?
- Tarsus Pharmaceuticals, Inc. (TARS) reported accounts payable of $24.13M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s accounts payable changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s accounts payable decreased by 15.0% year-over-year, from $28.38M to $24.13M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s accounts payable has grown at a 48.9% compound annual growth rate (CAGR), from $2.24M to $16.39M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.